博尔宁胶囊联合TP方案治疗乳腺癌的临床研究  

Clinical study on Bo'erning Capsules combined with TP chemotherapy in treatment of breast cancer

作　　者：钱钧强 朱宏明 房志仲[3] 齐立强 QIAN Jun-qiang;ZHU Hong-ming;FANG Zhi-zhong;QI Li-qiang(Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer,Department of Pharmacy,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Sino-Singapore Eco-City Hospital of Tianjin Medical University,Tianjin 300467,China;School of Pharmacy,Tianjin Medical University,Tianjin 300070,China)

机构地区：[1]天津医科大学肿瘤医院药学部国家肿瘤临床医学研究中心天津市"肿瘤防治"重点实验室天津市恶性肿瘤临床医学研究中心,天津300060 [2]天津医科大学中新生态城医院,天津300467 [3]天津医科大学药学院,天津300070

出　　处：《现代药物与临床》2018年第12期3246-3249,共4页Drugs & Clinic

摘　　要：目的探讨博尔宁胶囊联合TP(紫杉醇+顺铂)方案治疗乳腺癌的临床疗效。方法选取天津市肿瘤医院2016年10月—2017年10月收治的乳腺癌患者120例,随机分成对照组(60例)和治疗组(60例)。对照组患者静脉滴注注射用紫杉醇脂质体,135mg/m^2,同时静脉滴注顺铂注射液60mg/m^2,1次/3周。治疗组患者在对照组基础上口服博尔宁胶囊,4粒/次,3次/d。21 d为1个疗程,两组均治疗3个疗程。观察两组患者临床疗效,同时比较治疗前后两组患者血管内皮生长因子A(VEGFA)、血管内皮生长因子B(VEGFB)和肿瘤细胞凋亡指数(AIOTC)及不良反应情况。结果治疗后,对照组客观缓解率(ORR)和疾病控制率(CBR)分别为40.00%、71.67%,分别显著低于治疗组的68.33%、88.33%,两组比较差异均具有统计学意义(P<0.05)。治疗后,两组患者VEGFA和VEGFB水平显著降低,AIOTC明显升高,同组比较差异具有统计学意义(P<0.05);同时治疗组患者上述指标水平明显优于对照组显,两组比较差异具有统计学意义(P<0.05)。治疗期间,治疗组患者不良反应发生率为10.00%,明显低于对照组的21.67%,两组比较差异具有统计学意义(P<0.05)。结论博尔宁胶囊联合TP方案治疗乳腺癌效果明显,具有一定的临床推广应用价值。Objective To explore the clinical efficacy Bo’erning Capsules combined with TP chemotherapy in treatment of breast cancer. Methods Patients(120 cases) with breast cancer in Tianjin Medical University Cancer Institute and Hospital from October 2016 to October 2017 were randomly divided into control(60 cases) and treatment(60 cases) groups. Patients in the control group were iv administered with Paclitaxel Liposome for injection, 135 mg/m^2, and at the same time they were iv administered with Cisplatin Injection, 60 mg/m^2, once every 3 weeks. Patients in the treatment group were po administered with Bo’erning Capsules on the basis of the control group, 4 grains/time, three times daily. One course of treatment had 21 d, and patients in two groups were treated for 3 courses of treatment. After treatment, the clinical efficacy was evaluated, and VEGFA, VEGFB, AIOTC, adverse reactions in two groups before and after treatment were compared. Results After treatment, the objective reaction rate(ORR) and clinical benefit rate(CBR) in the control group were 40.00% and 71.67%, which were significantly lower than 68.33% and 88.33% in the treatment group, respectively, and there were differences between two groups(P < 0.05). After treatment, the VEGFA and VEGFB levels in two groups were significantly decreased, but AIOTC was significantly increased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the VEGFA, VEGFB, and AIOTC levels in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). During the treatment, the adverse reactions rate in the treatment group was 10.00%, which was significantly lower than 21.67% in the control group, with significant difference between two groups(P < 0.05). Conclusion Bo’erning Capsules combined with TP chemotherapy has significant effect in treatment of breast cancer, which has a certain clinical application value.

关 键 词：博尔宁胶囊 注射用紫杉醇脂质体 顺铂注射液 乳腺癌 管内皮生长因子A 肿瘤细胞凋亡指数 不良反应 

分 类 号：R979.1[医药卫生—药品]